Romania's Ozone to make generics

6 November 2006

Romanian Ozone Laboratories is to start producing new generic drugs, according to local media reports. The general manager of the company, Ruxandra Nastase, has been quoted in the business newspaper Ziarul Financiar as saying that she had decided to start an internal assessment process of the company after announcing the introduction of new generic drugs.

She stated: "as I had just joined the company, the first thing that I did was to begin an assessment process to see whether the internal structure of the company needed to be adjusted to the changes of the Romanian pharmaceutical market."

She added: "next year, we'll invest mainly in finding new partners and introducing new generic drugs. While we want to expand our portfolio, we'd also like to increase our focus on the introduction of some new, more modern products in the market," noting that Ozone "will concentrate on growing and becoming more mature during the next few months."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight